PTC Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,009	1,731	806.78	937.82	698.8	538.59
Revenue Growth	-42.84%	114.51%	-13.97%	34.20%	29.75%	41.45%
Cost of Revenue	70.68	47.01	57.4	65.49	44.68	32.33
Gross Profit	938.07	1,684	749.38	872.34	654.12	506.27
Selling, General & Admin	347.73	347.14	300.91	332.54	326	285.77
Depreciation & Amortization Expenses	40.31	24.74	60.74	222.64	116.55	54.75
Research & Development	433.31	455.25	534.48	666.56	651.5	540.68
Other Operating Expenses	-8.88	-10.43	155.82	90.1	7.48	-0.5
Total Operating Expenses	812.47	816.71	1,052	1,312	1,102	880.71
Operating Income	125.6	866.94	-302.57	-439.5	-447.41	-374.44
Interest Expense	-185.29	-152.23	-166.99	-129.18	-90.87	-86.02
Other Non-Operating Income (Expense)	8.11	-18.09	106.44	-127.43	-49.21	-57.88
Total Non-Operating Income (Expense)	-177.18	-170.32	-60.55	-256.61	-140.08	-143.9
Pretax Income	-2.46	696.62	-363.12	-696.11	-587.49	-518.34
Provision for Income Taxes	14.05	13.98	0.18	-69.51	-28.47	5.56
Net Income	-16.51	682.64	-363.3	-626.6	-559.02	-523.9
Net Income to Common	-38.38	682.64	-363.3	-626.6	-559.02	-523.9
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	81	80	77	75	72	70
Shares Outstanding (Diluted)	86	88	77	75	72	70
Shares Change	7.43%	14.92%	2.68%	4.33%	1.79%	6.72%
EPS (Basic)	-0.49	8.58	-4.73	-8.37	-7.79	-7.43
EPS (Diluted)	-0.58	7.78	-4.73	-8.37	-7.79	-7.43
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-39.78	702.34	-114.19	-186.86	-388.67	-279.55
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.46	7.95	-1.49	-2.50	-5.42	-3.97
Gross Margin	92.99%	97.28%	92.89%	93.02%	93.61%	94.00%
Operating Margin	12.45%	50.09%	-37.50%	-46.86%	-64.03%	-69.52%
Profit Margin	-1.64%	39.44%	-45.03%	-66.81%	-80.00%	-97.27%
FCF Margin	-3.94%	40.58%	-14.15%	-19.92%	-55.62%	-51.90%
EBITDA	180.9	905.75	-226.91	-202.91	-318.57	-310.31
EBITDA Margin	17.93%	52.34%	-28.13%	-21.64%	-45.59%	-57.61%
EBIT	125.6	866.94	-302.57	-439.5	-447.41	-374.44
EBIT Margin	12.45%	50.09%	-37.50%	-46.86%	-64.03%	-69.52%
Effective Tax Rate	-570.63%	2.01%	-0.05%	9.98%	4.85%	-1.07%

SEC Filings: 10-K · 10-Q